Antibody Drug Conjugates: A Leap Ahead in Cancer Treatment
Monoclonal antibody (MAb) based targeted therapies have achieved appreciable success in various branches of drug therapeutics, predominantly when used along with cytotoxic drugs. These immunological therapies based on antibody-drug conjugates (ADCs) have been recently encouraged by the US Food and Drug Administration to treat Solid tumours, Melanoma, Breast Cancer and Hodgkinâ€™s lymphoma. Antibody drug conjugates (ADCs) are an important division of therapeutics that allows the antigen-selective ability of MAbs to deliver highly potent cytotoxic drugs at the site of antigen-expressing tumor cells. The use of MAb directed delivery can confer a high therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. In other words, to achieve the goal of highly improved therapeutic efficacy and reduced toxicity, each component of an ADC i.e. the MAb, linker and the drug needs to be considered in context of targeted antigen. Furthermore, the mechanism of ADCs, characteristics of targets, methods of preparation, linker drugs being used in ADC design and regulatory requirements for new drug approval are discussed.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).